Milestone Pharmaceuticals’ CARDAMYST: A Promising Buy with FDA Decision and Phase 3 Trial on Horizon
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research ...